Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SPPI message board posts where the ticker symbol SPPI has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SPPI SEC Filings

Filings Format Description Filing Date File/Film Number
11-K  Documents Annual report of employee stock purchase, savings and similar plans
Acc-no: 0000831547-18-000057 (34 Act)  Size: 272 KB
2018-06-26 001-35006
18919580
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-039492 Size: 5 KB
2018-06-26
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038687 Size: 7 KB
2018-06-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038684 Size: 7 KB
2018-06-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038677 Size: 7 KB
2018-06-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038671 Size: 7 KB
2018-06-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038665 Size: 7 KB
2018-06-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038657 Size: 7 KB
2018-06-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038651 Size: 7 KB
2018-06-19
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038642 Size: 8 KB
2018-06-19
More SPPI SEC Filings


Related news from
Mon, 09 Jul 2018
23:20:00 +0000
Top 4 Small-Cap Stocks for 2018
Looking at growth outlooks and price targets, these four small-cap stocks could be stellar for the second half of 2018.
Fri, 29 Jun 2018
11:00:00 +0000
Spectrum Pharmaceuticals Presents ADVANCE Phase 3 ROLONTIS® (eflapegrastim) Data at MASCC 2018 and Announces the Phase 3 RECOVER Study Met the Primary Endpoint
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed data from the ADVANCE Phase 3 study which showed that ROLONTIS had an absolute risk reduction of severe neutropenia of 8.5 percent (95% CI: 0.2%, 16.2%) versus pegfilgrastim in Cycle 1. New safety data presented today also showed that the adverse events were not significantly different between two treatment arms.
Wed, 27 Jun 2018
16:03:24 +0000
Harry Boxer’s four momentum stocks breaking out
Here are four stocks in biotech, energy and media that are breaking out on news. Endocyte Inc.(ECYT) had a strong session Tuesday, up 81 cents, or 6%, to $14.45 on 1.4 million shares traded. The biopharmaceutical company, which on Monday was added to the Russell 3000 Index, announced that an image from its Phase 2 prostate cancer study was selected as “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.
Wed, 27 Jun 2018
12:00:00 +0000
Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Spectrum Pharmaceuticals saw its shares rise after a Bloomberg report revealed that the hematology and oncology company may be considering a sale. Shares of Sophiris Bio were bouncing in Tuesday trading after plummeting on Monday when Wall Street learned that a patient had died in the company’s ongoing phase 2b clinical trial for its prostate drug topsalysin. Spectrum Pharmaceuticals, Inc. shares closed up 14.59% on about 6.4 million shares traded yesterday.
Tue, 26 Jun 2018
14:36:00 +0000
Here's Why Spectrum Pharmaceuticals Inc. Is Soaring
Shares jump after rumors that the biotech is looking to sell itself. Here's what investors need to know.
Tue, 26 Jun 2018
13:31:19 +0000
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Achieve Life Sciences Inc (NASDAQ: ACHV ) stock was ...
Tue, 26 Jun 2018
11:15:00 +0000
Complimentary Technical Snapshots on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 26, 2018/ If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Monday, June 25, 2018, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red.
Tue, 26 Jun 2018
08:24:23 +0000
Spectrum Pharma Is Weighing a Sale
Spectrum Pharmaceuticals Inc., a U.S. biotech company focused on oncology and hematology, is exploring options including a sale of the business amid takeover interest from other drugmakers, people familiar ...
Mon, 25 Jun 2018
11:00:00 +0000
Spectrum Pharmaceuticals to Host Conference Call Highlighting ROLONTIS® (eflapegrastim) Phase 3 ADVANCE Study Data Presented at Multinational Association of Supportive Care in Cancer (MASCC)
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the company will hold a conference call on Friday, June 29th at 8:30 a.m. EDT/5:30 a.m. PDT to discuss the ROLONTIS Phase 3 ADVANCE study data being presented at Multinational Association of Supportive Care in Cancer (MASCC) 2018 annual meeting. The call will feature a presentation from ADVANCE study lead investigator, Lee S. Schwartzberg, M.D., FACP Professor of Medicine and Division Chief, Hematology Oncology, The University of Tennessee Health Science Center, and Executive Director, UT/West Cancer Center.
Tue, 19 Jun 2018
10:34:10 +0000
Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Spectrum Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Tue, 19 Jun 2018
01:01:13 +0000
Why Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) Is A Financially Healthy Company
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI), with a market capitalization of US$2.06B, rarely draw their attention from the investingRead More...
Thu, 07 Jun 2018
12:20:00 +0000
Today's Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Tesaro
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / U.S. equities closed in the green on Wednesday, as bond yields rose pushing financial sector higher. The Dow Jones Industrial Average jumped 1.40 percent to close ...
Wed, 30 May 2018
11:00:00 +0000
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2018 Global Healthcare Conference on June 6th
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company's business strategy and commercial and development-stage programs will be given at the Jefferies 2018 Global Healthcare Conference being held at the Grand Hyatt in New York. A live webcast of Spectrum's presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
Fri, 25 May 2018
11:10:00 +0000
Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).
Thu, 17 May 2018
17:17:00 +0000
Why Spectrum Pharmaceuticals, Inc. Is Up Big Today
Shares jumped after the company shared new details from an important phase 3 study. Here's what investors need to know.
Thu, 17 May 2018
06:10:00 +0000
CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract
Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”). ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy.
Wed, 16 May 2018
21:20:00 +0000
Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract
Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced detailed results from ADVANCE, a Phase 3 trial of ROLONTIS, demonstrating that it was non-inferior to pegfilgrastim in the reduction of duration of severe neutropenia (DSN) in all four cycles of the study. ROLONTIS is a novel long-acting granulocyte colony-stimulating factor (G-CSF) being studied as a treatment for neutropenia in patients undergoing myelosuppressive cytotoxic chemotherapy. “These data expand our understanding of the clinical profile of eflapegrastim and help establish it as a possible supportive care treatment option for the multitude of patients undergoing chemotherapy,” said Lee Schwartzberg, M.D., FACP, lead investigator, professor of medicine and division chief, hematology oncology, University of Tennessee Health Science Center, and executive director, UT/West Cancer Center.
Wed, 09 May 2018
11:00:00 +0000
Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th
Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the company’s business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2018 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. A live webcast of Spectrum’s presentation will be available at http://www.sppirx.com. Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology.
Wed, 09 May 2018
07:58:42 +0000
Edited Transcript of SPPI earnings conference call or presentation 3-May-18 8:30pm GMT
Q1 2018 Spectrum Pharmaceuticals Inc Earnings Call
Mon, 07 May 2018
11:10:00 +0000
Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib
LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "Since being one of the beginning members, it has been a great experience. This select group of sophisticated investors has exceptional knowledge to share. The members come from all walks of life and have varied experiences. Many are experts in finance and commodity related issues. Many are good money managers. This is a value oriented group where good yields on a variety of stocks are the main focus." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards